Market Overview
Viral vector is the most sought-after way to transfer genes to specific cell types or tissues and manipulate them to express therapeutic genes. Currently, there are several types of viruses, such as adenovirus, adeno associated virus, baculovirus and retrovirus, which are being investigated in order to deliver the genes to required cells. This process can provide permanent as well as transient transgene expression.
Market Dynamics
Viral vectors are primarily used in the development of various gene therapies and are showing great promise in disease landscape. Moreover, during the unprecedented times of COVID-19, the development of adenovirus-vector vaccine has helped to mitigate the dangerous risks associated with the pandemic.?
Since the viral vector-based gene therapies have shown promising results in the past, the developers are exploring its full potential to reach to its long-term success. With the ongoing rise in demand, the service providers are continuously expanding their facilities to meet the numbers. In August 2022, Thermofischer has expanded its cell and gene therapy capability by opening the new viral vector manufacturing facility in Massachusetts, US.
-
In June 2022, VIVEbiotech has completed the acquisition of its lentiviral vector manufacturing capabilities to support the customers throughout the development cycle.
-
In June 2022, Avid Bioservices expanded its viral vector focused facility with 53,000 sq. ft. area to address the demand of viral vector production at commercial scale.
The increasing prevalence of various genetic disorders and target diseases increased funding availability for development of gene therapy, research efforts in the field of viral vector-based cell and gene therapies, and increasing efficacy of viral vectors in delivering gene therapy are fueling growth in the global viral vectors manufacturing market.
Challenges
The ongoing challenge, which is linked with its ability to pass the immune system and high number of doses are some of the limiting factors delaying the success of such therapies. Further, the quality of transgene expression plays another crucial role for the desired clinical effect. The combinatorial factors demand innovations at the R&D scale, which will gain traction in investment from various organizations.
In June 2022, NSW Government of Australia allocated USD 101.4 million to the commercial facility of viral vector manufacturing. This clearly indicates the need to improve the viral vector-based therapy due to its significant potential to cure multiple indications.??
Development Landscape:
Biotech and pharmaceutical businesses are adopting both organic and inorganic growth strategies to advance their pipeline and gain competitive edge in the market over the peers.
-
In April 2022, ProteoNic and NecstGen announced a collaboration, wherein the respective players will utilize their proprietary platforms to advance the AAV and LV viral vector manufacturing technology.
Till now, only eight viral vector-based gene therapies have been approved by the US FDA, which were developed using three viral vectors- adeno associated virus, lentivirus and herpes simplex virus.
As of September 2022, over 145 clinical trial studies are going on with over 10,000 patients worldwide. The exploratory pipeline of viral vector-based therapy continues to grow across the indications and targets with promising results.
Key players:
Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US)
Upcoming players:
TBD
Regional Analysis:
North America?is anticipated to capture the highest share of this market over the forecast period (2022-2027), with U.S. accounting for the maximum contribution. Presence of most number of manufacturing facilities and key players, some of the best research universities and an encouraging start-up eco system provides an ideal environment for research leading to more successful assets in pipeline. Macro-economic factors such as large population and growing economy, high prevalence of cancer and infectious diseases, better access to insurance, availability of crowd funding and support from various stakeholders’ fuels US as a commercially attractible market.
-
In 2019, the New Jersey Innovation Institute signed an agreement with Pall Corporation to develop a BioPharmaceutical Innovation iLab to help fix the viral vector shortage using continuous manufacturing.
-
Thermo Fisher Scientific opened a cGMP manufacturing facility in Plainville, US which helped double the company’s commercial viral vector capacity?and?meet rising demand for the development and manufacturing of gene therapies and vaccines.
Europe?also remains a favourable region on par with the North American region. Presence of highly skilled researchers, well-developed R&D ecosystem, support from government agencies and regulatory bodies are the major driving factors in Europe.
-
In 2021, Yposkesi announced that its bioproduction project has been selected for the French government’s “Plan de Relance” initiative, which is an economic stimulus package aimed at making the nation’s bioproduction industry strategically more robust and economically resilient is investing USD6 million in its “Boost” project to develop a new generation 1000-L, GMP platform with optimized manufacturing and control processes for efficient viral vector production from the thawing of cells up to the aseptic filling of the end product.
Asia-Pacific?region is expected to pick up pace over the next few years due to favourable regulatory climate, increasing investments to drive market access in key markets such as Japan, China, Australia, Singapore and India. The market is focusing on Asia-Pacific as a destination for outsourcing and trying to gain foothold through mergers, collaborations, and strategic acquisitions.
-
In 2022, National Cancer Center Japan and GenScript ProBio entered into research collaboration agreement for a plasmid and lentiviral vector CMC development to develop plasmid and lentiviral vector for cell therapy to aim on FDA acceptance of IND applications.
-
In 2022, VectorBuilder, a CDMO announced an investment of USD 500m for China viral vector plant. The campus will include 30 production suites designed to manufacture lentivirus, plasmids, messenger RNA (mRNA), adeno-associated virus (AAV), cell lines and other types of viral and non-viral vectors.
Market Segments
The global viral vector manufacturing market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on?Types
-
Adenovirus
-
Adeno associated virus
-
Baculovirus
-
Retrovirus?
The global viral vector manufacturing market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on?Disease
-
Cancer
-
Infectious Disease
-
Genetic Disorders
The global viral vector manufacturing market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on?Application
-
Gene therapy
-
Vaccinology
The global viral vector manufacturing market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on?Region
-
North America (US and Canada)
-
EU4 and the UK
-
Asia Pacific (India, China and Japan)
What is Viral vector Gene Therapy Market Report about?
This report discusses the commercial and clinical activity, providing insights on the total size of the potential opportunity, key segments driving growth, key challenges faced, and a thorough analysis of market competition by product, geography, indication, and forecasts through 2030. Detailed coverage of the approved therapies, including regulatory approvals, pricing, reimbursement, and market penetration
So, a new investor can potentially gain information about competitors, their key products, their core strategy, key trends in the market, and more.
This report is essential for all stakeholders including research companies, manufacturing companies, distribution companies, government agencies, and others to:
-
Capitalize on rapidly emerging trends
-
Optimize decision-making
-
Reduce company risk
-
Approach partners/investors for collaboration or funding
-
Implement an informed and advantageous business strategy in 2022
-
Detailed coverage of the approved products, including regulatory approvals, pricing, reimbursement, and market penetration
-
Profiles of leading & upcoming competitors composing the global marketplace